PCRX — Pacira Biosciences Balance Sheet
0.000.00%
- $1.19bn
- $1.29bn
- $700.97m
- 75
- 51
- 86
- 81
Annual balance sheet for Pacira Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 522 | 656 | 289 | 279 | 485 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 53 | 96.3 | 98.4 | 106 | 113 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 652 | 866 | 498 | 510 | 745 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 211 | 265 | 254 | 235 | 216 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 1,275 | 2,075 | 1,681 | 1,574 | 1,554 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 253 | 521 | 148 | 97.4 | 310 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 655 | 1,345 | 906 | 704 | 775 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 620 | 730 | 775 | 870 | 778 |
Total Liabilities & Shareholders' Equity | 1,275 | 2,075 | 1,681 | 1,574 | 1,554 |
Total Common Shares Outstanding |